E2F1参与了细胞周期从G1期到S期的转换：在细胞周期G1期前，Rb与E2F1结合限制了其活性,当细胞周期蛋白激酶CDK结合蛋白Rb后，磷酸化的Rb释放E2F1/DP-1复合物,这样E2F1/DP-1就结合到基因组上，发挥转录调控功能激活下游基因,进而使细胞周期从G1期转换到S期。同时，E2F1还发挥促凋亡功能，通过p53依赖型
其中,Rb蛋白(Retinoblastoma protein)是E2F1最重要的负调控因子之一。在G1期,Rb蛋白与E2F1形成复合物,阻止E2F1的转录调控活性。当细胞准备进入S期时,Rb蛋白被磷酸化,导致与E2F1的解离,从而释放出E2F1,促进细胞周期的进行。 此外,E2F1的翻译后修饰也能够影响其活性。磷酸化、乙酰化和泛素化等修饰方式都可以调控E2F1的...
The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin Radiat Oncol. 2010;20:258-66.The E2F1/Rb and p53/MDM2 Pathways in DNA Repair and Apoptosis: Understanding the Crosstalk to Develop Novel...
When the cell receives signals to divide, E2F1 is released from inhibitory binding with the Retinoblastoma protein (RB). Target Gene Activation: Once active, E2F1 binds to the promoter regions of numerous genes whose products are essential for S phase progression, including: Cyclin E and ...
(Rb) phosphorylations within 15 minutes. Subsequently, the expressions of E2F1 and the cell cycle regulators: cyclin D1, cyclin E1 and cyclin‐dependent kinase 4 (CDK4) in G1 phase and cyclin A1, CDK2 and CDK1 in S‐...
E2F1与肿瘤代谢重编程的研究进展
KIF26A通过CDK-RB-E2Fs通路促进乳腺癌细胞增殖和细胞周期进展 (1) 通过全人类基因组微阵列芯片及E2F1抗体比较两组间差异,GO分析提示沉默KIF26A后下调的通路中,有与癌症相关的通路,Pathway分析提示与癌症增殖及细胞周期相关的通路; (2)使用E2F1抗体的Western Blot结果提示KIF26A基因沉默组p21的表达明显升高,CDK2/4/...
经cyclin E -磷酸化后Cdk2、Rb释放E2F1,而E2F1反过来激活许多基因的转录驱动S阶段的开始。编码周期素E的基因由E2F1控制,因此,cyclin E-Cdk2复合物和E2F1形成了一个正反馈回路motes G1/S相变[3,4,6,9]。周期蛋白E-Cdk2复合物也磷酸化Smad3、CBP/p300和NPAT导致细胞周期进展[10-13]。相反,CDK抑制剂通过...
抗体名:E2F 1; E2F transcription factor 1; E2F-1; E2f1 E2F transcription factor 1; KIAA4009; mKIAA4009; OTTHUMP00000030661; PBR 3; PBR3; PRB binding protein E2F 1; PRB-binding protein E2F-1; RBAP 1; RBAP-1; RBAP1; RBBP 3; RBBP-3; RBBP3; RBP 3; RBP3; Retinoblastoma associated...
Screening for epigenetic enzymes identifies GCN5 as a regulator of CSCs that deposits H3K9ac onto WNT promoters and enhancers. Collectively, paracrine signalling pathways are controlled by the E2F-GCN5-RB axis in diverse cancers and this could be a therapeutic target for eliminating CSCs....